No abstract

Objectives：This study aimed to investigate the efficacy and safety of Metadate CD (MCD) when given to Korean children and adolescents with attention-deficit hyperactivity disorder (ADHD). We also explored the effects of the drug on diverse neurocognitive functions.Methods：Ninety-one subjects with ADHD (mean age 8.6±2.2 years) were recruited at 6 outpatient clinics in Seoul, Korea. We used the ADHD Rating Scale (ARS), Clinical Global Impression (CGI), and comprehensive attention test (CAT) to measure the drugʼs effects.Results： After 0.92±0.32mg/kg/day of MCD were administered for 57.4±7.6 days, there was a 48.5% reduction in the mean total ARS scores (p＜.001). Fifty-seven subjects (64.8%) showed either much improved or very much improved outcomes on the CGI-Improvement scale. The CGI-Severity scale also decreased from an average of 4.7 to an average of 2.9 (p＜.001). Errors and response time standard deviations of the CAT, sustained attention test-to-response tasks, the flanker test, and divided attention test scores decreased after treatment (p＜.05). The forward memory span of the spatial working memory test scores increased (p＜.05). Thirty-five patients (39.8%) experienced side effects, of which the most common were headache (14.8%), nausea (12.5%), and anorexia (9.1%).Conclusion：This open-label study suggests that MCD is effective and safe in improving the symptoms and neurocognitive functions of Korean children and adolescents with ADHD.KEY WORDS：ADHDㆍMetadate CDㆍEffectivenessㆍSafetyㆍComprehensive Attention Test.